Breaking Updates in Hematological-Oncology

The American Society of Hematology (ASH) 2020 Annual Meeting and Exposition was held on the 5–8 December.

Despite the pandemic, the virtual format showcased outstanding leaps in understanding and treatment in 2020, across malignancies.

Explore our coverage by disease type, including updates from key trials in which new agents are moving forwards.

View all videos

ASH 2020

American Society of Hematology (ASH) Annual Meeting and Exposition
5–8 December 2020

HORIZON subgroup analyses: #Melfufen and dexamethasone in R/R #Myeloma w/ @mvmateos of @usal: http://ow.ly/AGxL50D4XEk

@VJHemOnc @ASH_hematology #ASH20 #HemOnc #MMsm #MultipleMyeloma

Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma - concept we follow and now aim for sustained MRD-ve in #mmsm ⁦@Mohty_EBMT⁩ ⁦@SagarLonialMD⁩ https://pubmed.ncbi.nlm.nih.gov/18470907/

The role of MRD is increasingly well established in myeloma. We have to move forward with the MRD-guided therapy prospective protocols. ⁦@BloodJournal⁩ ⁦@BrunoPaiva_UNAV⁩ ⁦@mvmateos⁩

4

Don’t miss our post-#ASH20 roundtable discussion w/ #MDS experts!
Register here 👉http://ow.ly/MX4850D2gdo👈

📅Thu, Jan 21, 2021 5:00 PM CET/ 11:00 AM EST

#ASH20 #HemOnc #CTsm #ASHFromHome #CTsm #MDSsm

Load More...

ASH 2020

American Society of Hematology (ASH) Annual Meeting and Exposition
5–8 December 2020

Breaking Updates in Hematological-Oncology

The American Society of Hematology (ASH) 2020 Annual Meeting and Exposition was held on the 5–8 December.

Despite the pandemic, the virtual format showcased outstanding leaps in understanding and treatment in 2020, across malignancies.

Explore our coverage by disease type, including updates from key trials in which new agents are moving forwards.

View all videos

HORIZON subgroup analyses: #Melfufen and dexamethasone in R/R #Myeloma w/ @mvmateos of @usal: http://ow.ly/AGxL50D4XEk

@VJHemOnc @ASH_hematology #ASH20 #HemOnc #MMsm #MultipleMyeloma

Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma - concept we follow and now aim for sustained MRD-ve in #mmsm ⁦@Mohty_EBMT⁩ ⁦@SagarLonialMD⁩ https://pubmed.ncbi.nlm.nih.gov/18470907/

The role of MRD is increasingly well established in myeloma. We have to move forward with the MRD-guided therapy prospective protocols. ⁦@BloodJournal⁩ ⁦@BrunoPaiva_UNAV⁩ ⁦@mvmateos⁩

4

Don’t miss our post-#ASH20 roundtable discussion w/ #MDS experts!
Register here 👉http://ow.ly/MX4850D2gdo👈

📅Thu, Jan 21, 2021 5:00 PM CET/ 11:00 AM EST

#ASH20 #HemOnc #CTsm #ASHFromHome #CTsm #MDSsm

Load More...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter